NCT07429318Active, not recruiting
Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer
Efficacy and Survival Prognosis Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- NCT number
- NCT07429318
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jan 2026 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery.
- (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery.
Other illness
- (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ.
Other
- (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC).
- (5) Patients whose key diagnosis and treatment information records were missing.
Who the study is looking for
- (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)
- (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI.
- (3) Patients who underwent adjuvant therapy before surgery.
- (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences.
- (5) Patients who have complete clinical, pathological and imaging data.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.